A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC)

Trial Profile

A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Sulfatinib (Primary)
  • Indications Thyroid cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 06 Jun 2017 Results (n=18) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 18 May 2017 According to a Chi-Med company media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017.
    • 02 Mar 2016 According to a Chi-Med company media release, company is planing to enrol approximately 50 differentiated thyroid carcinoma and medullary thyroid carcinoma patients into this study, with approximately 25 patients in each tumor type.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top